Asish Ghosh to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications Asish Ghosh has written about Leukemia, Lymphocytic, Chronic, B-Cell.
Connection Strength
4.567
-
Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817.
Score: 0.777
-
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021 05 17; 11(5):93.
Score: 0.725
-
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015 May 01; 21(9):2115-26.
Score: 0.470
-
Critical signal transduction pathways in CLL. Adv Exp Med Biol. 2013; 792:215-39.
Score: 0.406
-
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011 Feb 10; 117(6):1928-37.
Score: 0.352
-
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010 Mar 04; 115(9):1755-64.
Score: 0.329
-
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009 May 28; 113(22):5568-74.
Score: 0.313
-
Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009 Feb 15; 15(4):1250-8.
Score: 0.310
-
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications. Br J Cancer. 2024 Aug; 131(3):589-600.
Score: 0.225
-
Upregulation of AXL and ß-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. Blood Cancer J. 2021 02 18; 11(2):37.
Score: 0.178
-
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9.
Score: 0.105
-
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013 Jan 15; 119(2):363-70.
Score: 0.098
-
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Dec; 51(12):2222-9.
Score: 0.087
-
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol. 2009 Nov; 147(4):471-83.
Score: 0.081
-
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009 Aug 10; 27(23):3808-14.
Score: 0.079
-
Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2016 10; 57(10):2409-16.
Score: 0.032